Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer

Melissa M. Pham, Monica Avila, Emily Hinchcliff, Shannon N. Westin*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


The treatment of ovarian cancer has remained a clinical challenge despite high rates of initial response to platinum-based chemotherapy. Patients are generally diagnosed at an advanced stage with significant disease burden, which portends to worse survival outcomes. Deficiencies in the homologous recombination (HRD) DNA damage repair (DDR) pathway and mutations in the BRCA1/2 genes have been found in ovarian carcinomas. Moreover, patients with these specific molecular aberrations have demonstrated sensitivity and thus improved response to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment. The results of various clinical trials exploring the use of PARPi in different populations of ovarian cancer patients have shown impressive survival and response outcomes. With expanding indications, the use of PARPi has thus changed the landscape of ovarian cancer treatment. In this chapter, we will describe the different settings of PARPi treatment—frontline maintenance therapy, maintenance therapy for patients with recurrent platinum-sensitive disease, and treatment in the recurrent setting—and discuss treatment considerations and management of toxicities, as well as offer thoughts on future directions.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer Science and Business Media Deutschland GmbH
Number of pages19
StatePublished - 2023

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042
ISSN (Electronic)2509-8497


  • Frontline maintenance
  • Maintenance therapy
  • Ovarian cancer
  • PARP inhibitors
  • Recurrent disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer'. Together they form a unique fingerprint.

Cite this